Valneva to Present and Meet Investors at June Conferences

June 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a company specializing in vaccines, has announced its participation in several investor conferences in the United States and Europe during June 2024. The company’s management team will present and engage in meetings with global institutional investors to discuss key developments and plans.

Valneva will be showcasing VLA15, a leading Lyme Disease vaccine candidate currently in Phase 3 development in partnership with Pfizer. Additionally, discussions will cover the commercial launch plans for IXCHIQ®, the world’s first and only approved chikungunya vaccine. The company will also present VLA1601, a next-generation Zika virus vaccine candidate now in Phase 1 clinical trials.

Investors interested in one-on-one meetings with Valneva’s management at any of the upcoming conferences need to request appointments through their respective banking representatives.

Schedule of Investor Conferences:

1. Jefferies Global Healthcare Conference
- Date/Time: June 6, 2:00 PM
- Format: Fireside chat and investor meetings
- Location: New York, NY
- Webcast: A replay will be available on Valneva’s website in the “Investor” section.

2. 13th ODDO BHF Nextcap Forum
- Date: June 6
- Format: Investor meetings only
- Location: Virtual

3. Goldman Sachs 45th Annual Global Healthcare Conference
- Date: June 10 – 13
- Format: Fireside chat and investor meetings
- Location: Miami, FL

4. Stifel 2nd European Healthcare Summit
- Date: June 25 – 27
- Format: Investor meetings only
- Location: Lyon, France

About Valneva SE

Valneva SE is a specialty vaccine company dedicated to developing, manufacturing, and commercializing prophylactic vaccines aimed at addressing unmet medical needs in infectious diseases. Their highly specialized approach leverages deep expertise across multiple vaccine modalities, striving to deliver first-, best-, or only-in-class vaccine solutions.

The company has a commendable track record, advancing several vaccines from early research and development stages to approvals. Currently, Valneva markets three proprietary travel vaccines alongside certain third-party vaccines through its established commercial infrastructure. The revenue generated from its commercial activities supports the ongoing advancement of its vaccine pipeline, which includes the only advanced clinical-stage Lyme disease vaccine candidate in partnership with Pfizer, as well as candidates targeting the Zika virus and other global public health threats.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!